Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organidin

Executive Summary

"Higher sales of expectorant/mucolytic products" also contributed to sales growth, C-W says. Expectorant/mucolytic sales were $54 mil. in the period compared to $34 mil. a year ago. "The unit volume gain in expectorant/mucolytic products was due primarily to a decline in sales of competitive products. The company is unable to determine whether such decline will continue," the report states. Although FDA ordered all marketers of iodinated glycerol products to cease marketing the drugs and to submit NDAs in an April 1993 warning letter, C-W has continued to market Organidin
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024166

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel